Biohaven Ltd.
$12.39-$1.26 (-9.2%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.7B
- P/E
- -2.3x
- EV / EBITDA
- -2.4x
- Revenue
- $0.00
- ROCE
- -222.2%
Price chart
Technical chartScreen technicals →+28.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +4.9%
- 3M
- -8.2%
- 6M
- +40.0%
- 1Y
- +28.7%
- 5Y
- Short history
- A period is left blank when the price history is shorter than the period.
52-week range
Day change -$1.26 (-9.2%) from $13.65 to $12.39 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in BHVN, bought on each weekday since 2022.
News & filings
What Biohaven filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 739 million US dollars in fiscal 2025.
Strengths (1)
- Current assets are 3.18 times current liabilities.
- Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.
- Revenue is too small for margins and growth rates to be read, so those points are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.
Read moreShow less
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
- Sector
- Healthcare
- Shares outstanding
- 132.8M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.7B
- P/E
- -2.3x
- P/B
- 33.0x
- EV / EBITDA
- -2.4x
- 52-week high
- $16.95
- 52-week low
- $8.09
Profitability
- ROE
- -1418.8%
- ROCE
- -222.2%
- ROIC
- -551.7%
- ROA
- -163.7%
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $0.00
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -12.7%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$610.2M
Solvency
- Current ratio
- 3.18
- Debt / Equity
- 5.47
- Debt / Assets
- 0.63
- CFO / Net profit
- 0.82
- Cash / Market cap
- 13.4%
Revenue and net profit
Annual revenue, with net profit as the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $0.00 | -$570.3M |
| FY2023 | $0.00 | -$408.2M |
| FY2024 | $0.00 | -$846.4M |
| FY2025 | $0.00 | -$738.8M |
Cash flows
FY2025: -$609.4M from operations, -$610.2M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$297.7M | -$338.8M |
| FY2023 | -$331.7M | -$334.8M |
| FY2024 | -$582.5M | -$586.5M |
| FY2025 | -$609.4M | -$610.2M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $0.00
- EBITDA
- -$735.5M
- Net profit
- -$738.8M
- Cash from operations
- -$609.4M
- Free cash flow
- -$610.2M
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $0.00 | -$735.5M | -$738.8M | -$610.2M | -1418.8% | — | -12.7% |
Monthly returns
Month-by-month returns of BHVN across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $451.4M |
| Current assets | $368.3M |
| Non-current assets | $83.1M |
| Liabilities | $399.4M |
| Current liabilities | $115.9M |
| Non-current liabilities | $283.4M |
| Equity | $52.1M |
| Paid-in capital | $194.0M |
| Retained earnings | -$2.1B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; BHVN highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Biohaven Ltd., SELLAS Life Sciences Group, Inc., Sionna Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Biohaven Ltd.BHVNthis company | $1.7B | -2.3x | 33.0x | -1418.8% | -2.4x |
| SELLAS Life Sciences Group, Inc.SLS | $1.8B | -66.2x | 25.1x | -37.9% | -60.4x |
| UFP Technologies, Inc.UFPT | $1.7B | 25.4x | 4.1x | 16.1% | 16.8x |
| Agios Pharmaceuticals, Inc.AGIO | $1.7B | -4.1x | 1.4x | -34.6% | -3.6x |
| Sionna Therapeutics, Inc.SION | $1.7B | -22.7x | 5.6x | -24.5% | -18.7x |
| Taysha Gene Therapies, Inc.TSHA | $1.7B | -15.5x | 6.9x | -44.1% | -13.4x |
| Novavax, Inc.NVAX | $1.7B | 3.8x | -13.1x | -344.7% | 3.4x |
| Addus HomeCare CorporationADUS | $1.7B | 17.5x | 1.5x | 8.8% | 11.2x |
| GeneDx Holdings Corp.WGS | $1.7B | -79.5x | 5.4x | -6.8% | 138.2x |
| Peer median | — | -9.8x | 4.8x | -29.6% | -0.1x |
Year-to-date ROI
BHVN since 1 January, against earlier years.
Historical volatility
BHVN's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $0.00 |
| Operating expensesOperating Expense | $745.4M |
| Research and developmentResearch And Development | $635.1M |
| Selling, general and administrativeSelling General And Administration | $110.3M |
| Total expensesTotal Expenses | $745.4M |
| Operating incomeOperating Income | -$745.4M |
| Interest and other | |
| Pretax incomePretax Income | -$737.4M |
| TaxTax Provision | $1.4M |
| Net incomeNet Income | -$738.8M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $451.4M |
| Current assetsCurrent Assets | $368.3M |
| Non-current assetsTotal Non Current Assets | $83.1M |
| LiabilitiesTotal Liabilities Net Minority Interest | $399.4M |
| Current liabilitiesCurrent Liabilities | $115.9M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $283.4M |
| EquityTotal Equity Gross Minority Interest | $52.1M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$609.4M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$609.4M |
| Net income, continuing operationsNet Income From Continuing Operations | -$738.8M |
| Depreciation and amortisationDepreciation And Amortization | $9.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $9.9M |
| Stock-based compensationStock Based Compensation | $112.4M |
| Operating gains and lossesOperating Gains Losses | $9.4M |
| Gain loss on investment securitiesGain Loss On Investment Securities | $9.4M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $0.00 |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | -$8.7M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | — |
| Asset impairmentAsset Impairment Charge | — |
| Change in working capitalChange In Working Capital | $1.4M |
| Other non-cash itemsOther Non Cash Items | $5.0M |
| Investing cash flowInvesting Cash Flow | $300.6M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $300.6M |
| Capital expenditureCapital Expenditure | -$720.0k |
| Purchase of PP&EPurchase Of PPE | -$720.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$720.0k |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Purchase of investmentsPurchase Of Investment | -$266.9M |
| Sale of investmentsSale Of Investment | $570.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | $303.1M |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Sale of intangiblesSale Of Intangibles | $0.00 |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | $0.00 |
| Other investing changesNet Other Investing Changes | -$1.9M |
| Financing cash flowFinancing Cash Flow | $439.1M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $439.1M |
| Debt issuedIssuance Of Debt | $250.0M |
| Net debt issuedNet Issuance Payments Of Debt | $250.0M |
| Long-term debt issuedLong Term Debt Issuance | $250.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | $250.0M |
| Shares issuedIssuance Of Capital Stock | $189.2M |
| Common stock issuedCommon Stock Issuance | $189.2M |
| Net common stock issuedNet Common Stock Issuance | $189.2M |
| Stock options exercisedProceeds From Stock Option Exercised | $1.8M |
| Other financing chargesNet Other Financing Charges | -$1.9M |
| Change in cashChanges In Cash | $130.2M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 0.0% |
| Cash at the start of the yearBeginning Cash Position | $102.5M |
| Cash at the end of the yearEnd Cash Position | $232.8M |
| Free cash flowFree Cash Flow | -$610.1M |
| Supplemental |
Learn while you research
Academy chapters picked for Biohaven Ltd. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Leverage RatiosDebt/Equity of 5.47 is elevated, understand what that means for solvency.6 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read